Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Genentech, Inc.
Providence Health & Services

      This is a non-randomized, open-label, single arm phase II trial of the combination of
      bevacizumab and ixabepilone in patients with advanced- or metastatic non-squamous NSCLC
      progressive after first or second-line therapy. The main objective is to evaluate the
      progression-free survival in patients with advanced or metastatic non-squamous NSCLC being
      treated with ixabepilone and bevacizumab.
    
Drug